|
|
Volumn 13, Issue 7, 2014, Pages 491-492
|
|
The malignant melanoma landscape
a
a
NONE
(United Kingdom)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE;
BINIMETINIB;
COBIMETINIB;
DABRAFENIB;
ENCORAFENIB;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
IPILIMUMAB;
LGX 818;
NIVOLUMAB;
PEMBROLIZUMAB;
PLACEBO;
PROGRAMMED DEATH 1 RECEPTOR;
TALIMOGENE LAHERPAREPVEC;
TRAMETINIB;
UNCLASSIFIED DRUG;
VEMURAFENIB;
DACARBAZINE;
CANCER CHEMOTHERAPY;
CANCER GRADING;
CANCER PROGNOSIS;
CANCER SURVIVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
HUMAN;
MELANOMA;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEIN TARGETING;
SHORT SURVEY;
SURVIVAL TIME;
CANCER ADJUVANT THERAPY;
CANCER INCIDENCE;
DRUG APPROVAL;
DRUG COST;
DRUG FATALITY;
HEALTH CARE COST;
IMMUNOTHERAPY;
INOPERABLE CANCER;
MONOTHERAPY;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
RECURRENCE FREE SURVIVAL;
SKIN DISEASE;
TREATMENT RESPONSE;
UNSPECIFIED SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
HEALTH CARE SECTOR;
HUMANS;
MELANOMA;
MOLECULAR TARGETED THERAPY;
|
|
EID: 84903773843
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4326 Document Type: Short Survey |
|
Times cited : (33)
|
|
References (2)
|
